Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · PRECISION BIOSCIENCES INC (DTIL)

Precision BioSciences prices stock offering, extends cash runway into Q4 2029

Neutral Impact 3 of 5 financing

Precision BioSciences said it expects its November 5, 2026 share offering, along with existing cash, its at-the-market facility and continued cost discipline, to fund operations into the fourth quarter of 2029. The company projects it is sufficiently capitalized to fund its PBGENE-HBV and PBGENE-DMD clinical programs through key next-stage inflection points. The filing does not state the net proceeds amount.

Key points

  • Offering of 10,235,077 common shares at $7.75 per share, under an underwriting agreement dated November 5, 2026
  • Pre-funded warrants for up to 5,893,964 shares offered in lieu of common stock to certain investors, at $7.749995 per warrant
  • Expected cash runway into the fourth quarter of 2029, covering PBGENE-HBV and PBGENE-DMD programs

The filing

CompanyPRECISION BIOSCIENCES INC (DTIL)
Form8-K, current report
Filed with the SECNov 9, 2026, 7:00 AM ET
Accession number0001628280-26-071867

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 7:10 AM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.